-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Further weakness as Peijia Medical (HKG:9996) drops 10.0% this week, taking one-year losses to 79%
Further weakness as Peijia Medical (HKG:9996) drops 10.0% this week, taking one-year losses to 79%
As every investor would know, you don't hit a homerun every time you swing. But serious investors should think long and hard about avoiding extreme losses. It must have been painful to be a Peijia Medical Limited (HKG:9996) shareholder over the last year, since the stock price plummeted 79% in that time. That'd be enough to make even the strongest stomachs churn. Because Peijia Medical hasn't been listed for many years, the market is still learning about how the business performs. And the share price decline continued over the last week, dropping some 10.0%. However, this move may have been influenced by the broader market, which fell 4.0% in that time.
With the stock having lost 10.0% in the past week, it's worth taking a look at business performance and seeing if there's any red flags.
View our latest analysis for Peijia Medical
Because Peijia Medical made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually expect strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.
In the last twelve months, Peijia Medical increased its revenue by 253%. That's a strong result which is better than most other loss making companies. So the hefty 79% share price crash makes us think the company has somehow offended market participants. Something weird is definitely impacting the stock price; we'd venture the company has destroyed value somehow. We'd recommend taking a very close look at the stock (and any available forecasts), before considering a purchase, because the share price is not correlated with the revenue growth, that's for sure. Of course, markets do over-react so share price drop may be too harsh.
The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).
SEHK:9996 Earnings and Revenue Growth July 13th 2022This free interactive report on Peijia Medical's balance sheet strength is a great place to start, if you want to investigate the stock further.
A Different Perspective
We doubt Peijia Medical shareholders are happy with the loss of 79% over twelve months. That falls short of the market, which lost 20%. There's no doubt that's a disappointment, but the stock may well have fared better in a stronger market. The share price decline has continued throughout the most recent three months, down 4.8%, suggesting an absence of enthusiasm from investors. Given the relatively short history of this stock, we'd remain pretty wary until we see some strong business performance. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Even so, be aware that Peijia Medical is showing 1 warning sign in our investment analysis , you should know about...
We will like Peijia Medical better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on HK exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
正如每个投资者都知道的那样,你不会每次挥杆都打出本垒打。但认真的投资者应该深思熟虑,避免极端的损失。作为一名沛嘉医疗有限公司(HKG:9996)去年的股价暴跌了79%。这足以让最强壮的人胃里翻腾。由于沛嘉医疗多年未上市,市场仍在了解该业务的表现。过去一周,股价继续下跌,跌幅约为10.0%。然而,这一走势可能受到了大盘的影响,大盘在此期间下跌了4.0%。
鉴于该公司股价在过去一周下跌了10.0%,我们有必要看看公司的业绩,看看是否有任何危险信号。
查看我们对沛嘉医疗的最新分析
由于沛嘉医疗在过去12个月里出现了亏损,我们认为市场可能更关注营收和营收增长,至少目前是这样。未盈利公司的股东通常预期营收增长强劲。这是因为快速的收入增长可以很容易地推断出预期利润,通常是相当大的规模。
在过去的12个月里,沛嘉医疗的收入增长了253%。这是一个强劲的结果,比大多数其他亏损的公司都要好。因此,79%的股价暴跌让我们认为该公司以某种方式冒犯了市场参与者。一些奇怪的东西肯定在影响着股价;我们敢说,该公司不知何故已经摧毁了价值。我们建议在考虑收购之前,仔细看看股票(以及任何可用的预测),因为股价是不与收入增长相关,这一点是肯定的。当然,市场的确反应过度,因此股价下跌可能过于苛刻。
该公司的收入和收益(随着时间的推移)如下图所示(点击查看具体数字)。
联交所:9996盈利及收入增长2022年7月13日这免费如果你想进一步调查沛嘉医疗的股票,那么有关该公司资产负债表实力的互动报告是一个很好的起点。
不同的视角
我们怀疑新浪沛嘉医疗的股东对过去12个月亏损79%感到满意。这一数字低于大盘,大盘下跌20%。毫无疑问,这令人失望,但在一个更强劲的市场中,该股很可能表现得更好。最近三个月,股价持续下跌,跌幅达4.8%,表明投资者缺乏热情。鉴于这只股票的历史相对较短,在看到一些强劲的业务表现之前,我们将保持相当谨慎的态度。我发现,把股价作为衡量企业业绩的长期指标是非常有趣的。但为了真正获得洞察力,我们还需要考虑其他信息。即便如此,要注意沛嘉医疗正在上映在我们的投资分析中出现1个警告信号,你应该知道关于……
如果我们看到一些内部人士大举收购,我们会更喜欢沛嘉医疗。在我们等待的时候,看看这个免费最近有大量内幕收购的成长型公司名单。
请注意,本文引用的市场回报反映了目前在香港交易所交易的股票的市场加权平均回报。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧